Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study

Table 1

Clinical and biochemical characteristics of the study participants with Graves’ disease and Graves’ orbitopathy—GD with GO vs. control subjects—CS.

Parameter	Values		value
	GD with GO ()	CS ()
Age (years)	53 (46-59)	46 (31-61)	0.067
Male sex, (%)	9 (29)	20 (28)	0.897^1
WBC, 1000/μL	6.59 (5.89-7.52)	6.37 (5.25-7.83)	0.217
hsCRP (mg/L)	1.5 (0-3.8)	1.1 (0.4-2.5)	0.613
ALT (U/L)	20 (13-26)	20 (13-27)	0.863
AST (U/L)	19 (16-26)	19 (15-23)	0.580
TPOAb (U/mL)	174 (58-259)	12 (9-16)	<0.001
TGAb (U/mL)	133 (27-267)	11 (10-16)	<0.001
TRAb (U/L)	13.56 (4.29-27.8)	0.30 (0.19-0.49)	<0.001
TSH (μIU/mL)	1.38 (0.65-2.08)	1.63 (1.11-2.17)	0.178
FT3 (pmol/L)	4.3 (3.9-5.23)	4.93 (4.51-5.50)	<0.001
FT4 (pmol/L)	17.8 (13.6-19.31)	16.13 (14.82-17.61)	0.159
IL-29 (pg/mL)	165 (133-747)	62 (62-217)	<0.001

Data are presented in the form of number (%) or median (IQR).
The italic values are those which are statistically significant.
¹Chi-squared test; Mann–Whitney test in other cases, where it is not marked with the superscript one.
ALT: alanine transaminase; AST: aspartate transaminase; FT3: free triiodothyronine; FT4: free thyroxine; hsCRP: high-sensitivity C-reactive protein; IQR: interquartile range; TGAb: antithyroglobulin antibodies; TPOAb: antithyroid peroxidase antibodies; TRAb: anti-TSH receptor antibodies; TSH: thyroid-stimulating hormone; U: unit; WBC: white blood cells.